July 15th 2024
Rohan Garje, MD, discusses the benefits of a multimodal approach for patients with small cell bladder cancer.
June 10th 2024
Rohan Garje, MD, discusses the impact of human papillomavirus status on survival outcomes in penile squamous cell carcinoma.
May 15th 2024
Rohan Garje, MD, discusses emerging biomarkers in metastatic castration-resistant prostate cancer and where the treatment field is headed.
May 14th 2024
Rohan Garje, MD, discusses the utility of lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.
May 4th 2024
Rohan Garje, MD, discusses considerations when choosing between FDA-approved PARP inhibitor–based combinations for patients with mCRPC.
April 23rd 2024
Rohan Garje, MD, discusses the evolving use of genomic testing and targeted treatment approaches in prostate cancer.